Article

Cymbalta for Chronic Pain

As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.

As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.

Eli Lilly & Co, the company that markets the drug, is seeking approval for the expanded use as a treatment for chronic pain conditions that would include pain caused by osteoarthritis or low back pain. Currently, the drug is also approved to treat diabetic nerve pain, fibromyalgia, and anxiety.

However, there are safety concerns associated with the drug, including possible liver damage and bleeding risks. The drug will be reviewed Thursday.

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
© 2024 MJH Life Sciences

All rights reserved.